Promising Venom-derived Peptides as Innovative Health Solutions for Treating the Metabolic Disorders: A Policy Brief

Abstract

Background: Metabolic disorders, particularly hyperlipidemia, are recognized as rising global health issues and pose significant public health challenges, especially in low- and middle-income countries (LMICs). Despite the widespread use of chemical drugs such as statins and fibrates, issues like side effects, drug resistance, and poor adherence limit their long-term effectiveness. Objectives: This policy brief explores the untapped potential of venom-derived peptides, specifically LVP1, a lipolysis-activating peptide isolated from scorpion venom, as innovative, natural therapeutic candidates for treating metabolic diseases. Methods: Recent transcriptomic studies of Iranian scorpion species demonstrated that although LVP1s derived from Iranian scorpion venom vary in sequence and origin, these peptides share conserved structural motifs, suggesting functional consistency and potential bioactivity in lipid metabolism modulation without the neurotoxic effects. Results: These findings highlight the dual important opportunity: Conserving biodiversity and investing in venom-based drug discovery as a promising avenue in biopharmaceutical innovation. Conclusions: The policy brief outlines specific policy recommendations with the aim of supporting venom peptide research, promoting biotechnology partnerships, and integrating biodiversity considerations into national health strategies. With strategic investment and international cooperation in this field, countries like Iran, which are rich in venomous animals, can play a leading role in the advancement and development of next-generation treatments for non-communicable diseases such as hyperlipidemia.